IMMP Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Immutep Ltd is not a good buy right now for a Beginner investor with a long-term horizon and $50,000-$100,000 to deploy. The stock is under heavy fundamental and sentiment pressure after the lead Phase 3 program was halted for futility, analysts cut ratings sharply, and multiple law firms launched class action suits. While the pre-market move is slightly positive and options flow is strongly call-skewed, there is no AI Stock Picker or SwingMax buy signal today, and the technical setup remains weak. My direct view: do not buy now.
The technical trend is bearish overall. MACD histogram is slightly positive at 0.0125 but contracting, which suggests only a weak near-term stabilization. RSI_6 at 39.623 is neutral-to-weak, not confirming a rebound. Moving averages are bearish with SMA_200 > SMA_20 > SMA_5, indicating the stock remains in a downtrend. Price is pre-market at 0.4499, below the pivot at 0.486 and only slightly above S1 at 0.431, with S2 at 0.397 as the next downside area. The stock trend model shows only modest near-term upside probabilities, which is not enough to offset the broader weakness.
["Pre-market price is up 1.19%, showing some short-term stabilization.", "Options positioning is heavily call-skewed, which may indicate speculative bullish sentiment.", "MACD histogram is slightly above zero, suggesting downside momentum may be slowing."]
["Phase 3 study with Merck was halted for futility, removing a major growth catalyst.", "Multiple law firms have announced class action lawsuits and lead-plaintiff notices.", "Analyst sentiment has deteriorated sharply with several downgrades.", "Bearish moving-average structure confirms the broader downtrend.", "No AI Stock Picker signal and no SwingMax buy signal today.", "No significant insider buying or hedge fund accumulation trend."]
No usable financial snapshot was provided, so recent quarterly revenue or earnings growth cannot be assessed here. As a result, the investment case must rely mainly on pipeline news, analyst revisions, and market signals. Based on those inputs, there is no clear evidence of improving fundamental performance in the latest quarter.
Analyst sentiment has turned notably negative. On 2026-03-13, Maxim downgraded IMMP to Hold from Buy after the Phase 3 study was halted. Citizens downgraded it to Market Perform from Outperform, citing the discontinuation of the lead program. Baird downgraded it to Neutral from Outperform and slashed the price target from $7 to $1, also noting no clear path forward for efti. Overall, Wall Street pros now appear cautious to bearish, with the main con being lost clinical momentum and the main pro being only a speculative rebound case if future data changes the narrative.
